Anuh Pharma FY2026: Strong growth, tighter margins

Anuh Pharma’s FY2026: Growth in regulated markets, but margins tighten

Anuh Pharma’s FY2026 investor presentation tells a clear story of scale-up and compliance. The company reported revenue of 776 crore for FY26, up 15.66 percent year on year. Production volumes rose sharply, with total production of 1,733 metric tonnes for the year, up 24.99 percent. The operating narrative is anchored in two themes: expanding presence in regulated markets and strengthening quality systems.

The headline positive in the deck is regulatory execution. Management notes the successful completion of both USFDA and EU GMP inspections. The journey timeline also states that the USFDA inspection in 2026 was completed successfully with zero 483 observations. For an API manufacturer, that matters because it supports credibility with customers that sell into highly regulated jurisdictions.

But FY26 was not a smooth profit year. Despite revenue growth, EBITDA and net profitability fell. The detailed financial table for the year ended March 31, 2026 shows EBITDA of 66.08 crore compared with 70.36 crore in FY25. PAT is shown at 41.05 crore versus 47.35 crore in the prior year. Over the longer period, the company’s track record slide shows EBITDA margin declining to 8.56 percent in FY26 from 10.64 percent in FY25 and 13.48 percent in FY24.

What drove the year: volumes and product shifts

Management attributes FY26 revenue growth to strong volume growth and expanding into regulated markets. The company’s product mix table provides a useful lens into what changed between FY25 and FY26.

Erythromycin remains the anchor product, rising from 221 crore in FY25 to 241 crore in FY26. A notable shift is in Higher Macrolides, which increased to 110 crore from 68 crore. Sulphadoxine also grew to 100 crore from 90 crore, and Pyrazinamide rose modestly to 42 crore from 38 crore.

At the same time, Cortico Steroids declined from 102 crore to 82 crore, and Gliclazide fell from 28 crore to 21 crore. The “Other Items” bucket expanded sharply to 110 crore from 58 crore, suggesting either newer products or a broader base of smaller APIs contributing more meaningfully.

The quarter-level commentary is more mixed. In Q4 FY26, the message from the Joint MD shows revenue at 201 crore with EBITDA (excluding other items) at 23.56 crore, down 18.32 percent, while production was largely flat at 426 metric tonnes. The detailed quarterly financial table similarly shows Q4 operating revenue at 202.12 crore, with EBITDA at 18.63 crore, lower than the prior quarter’s 20.91 crore. The company references global market challenges in Q4, but does not quantify the specific cost or pricing drivers.

Financial snapshot

Note: The presentation includes both a management summary and a detailed financial table with slightly different revenue totals for FY26. The extraction above preserves the figures as presented.

Exports, geography, and concentration

The company states that around 46 percent of FY26 revenues came from exports. On the revenue split slide, domestic revenue is shown at 417 crore in FY26 versus 297 crore in FY25, while export revenue is shown at 355 crore in FY26 versus 365 crore in FY25.

Geographically, export sales in FY26 are distributed across Asia (35 percent) and Africa (33 percent), with Europe at 24 percent, North America at 5 percent, and Latin America at 3 percent. Compared to FY25, Europe’s share rises and Latin America’s share falls, while Asia remains the largest single region.

The presentation also points to customer concentration. It states that the top five customers contributed 42 percent of FY26 export sales. This is not unusual in APIs, but it raises the importance of relationship stability and regulatory performance because large customers tend to be audit-heavy and sensitive to supply disruptions.

Capacity, compliance infrastructure, and R&D

Anuh Pharma’s operating model is built around a single major manufacturing base. The company describes a state-of-the-art manufacturing facility at Tarapur spread across 11,400 square meters, with 9 API blocks and 2 intermediate blocks and a total capacity of 2,400 MTPA including expanded capacity. The facility is described as EU GMP and WHO prequalified.

Environmental compliance is highlighted through the commissioning of a Zero Liquid Discharge system. The deck also mentions fire-fighting and safety systems, 100 percent power backup, training facilities, and green belt development.

On the development side, Anuh Pharma has an R&D facility at Mahape spanning 10,000 square feet, with 16 scientists. Management repeatedly emphasizes process innovation and cost optimization, which is consistent with an API business where competitiveness often depends on process yields, solvent recovery, and stable quality systems.

What management says about the next phase

The forward-looking section repeats the strategic focus: process innovation, cost optimization, and diversification into regulated markets. The deck includes a numeric guidance statement that the company anticipates steady growth of 15 to 20 percent per annum.

The company also lists three products under development: Vonoprazon Fumarate (anti-ulcerative), Pretomanid (anti-TB), and Edoxaban Tosylate (anti-coagulant). While timelines and commercialization plans are not provided, the disclosure indicates the company is exploring pipeline additions beyond its current set of macrolides, anti-TB, and other APIs.

Key takeaways

Anuh Pharma’s FY2026 presentation reflects a company that is scaling volumes and building credibility in regulated markets. The successful USFDA and EU GMP inspections, including the statement of zero 483 observations, are meaningful positives for customer confidence and long-term export potential.

At the same time, the financial trajectory shows pressure on margins and profitability. EBITDA margin declined to 8.56 percent in FY26, and the cash conversion cycle increased to 86 days, pointing to higher working capital intensity. The next set of disclosures investors may look for are clearer explanations of margin drivers, the nature of growth in the “Other Items” product bucket, and how the company plans to improve cash conversion while pursuing the 15 to 20 percent growth ambition.